| 4.49 0.03 (0.67%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.81 | 1-year : | 9.57 |
| Resists | First : | 6.69 | Second : | 8.19 |
| Pivot price | 4.98  |
|||
| Supports | First : | 4.26 | Second : | 3.54 |
| MAs | MA(5) : | 4.51  |
MA(20) : | 5.46 |
| MA(100) : | 7.26 |
MA(250) : | 8.88 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 9.6 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 15.8 | Low : | 4.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLNN ] has closed above bottom band by 31.0%. Bollinger Bands are 10.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.67 - 4.7 | 4.7 - 4.72 |
| Low: | 4.35 - 4.37 | 4.37 - 4.39 |
| Close: | 4.45 - 4.49 | 4.49 - 4.53 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Mon, 15 Jul 2024
Clene Inc (CLNN-Q) Quote - Press Release - The Globe and Mail
Fri, 12 Jul 2024
Clene Inc (CLNN-Q) Quote - Press Release - The Globe and Mail
Thu, 11 Jul 2024
Clene (NASDAQ:CLNN) Sets New 1-Year Low at $4.91 - MarketBeat
Tue, 09 Jul 2024
Clene Announces 1-for-20 Reverse Stock Split - StockTitan
Tue, 23 Apr 2024
Bullish Clene Insiders Loaded Up On US$9.58m Of Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -14 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.43e+006 (%) |
| Held by Institutions | 3.35e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8.2 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 646.5 % |
| Return on Equity (ttm) | -57.5 % |
| Qtrly Rev. Growth | 702.2 % |
| Gross Profit (p.s.) | -55.92 |
| Sales Per Share | -1215.25 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.732e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.55 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 12480 |
| Forward Dividend | 29820 |
| Dividend Yield | 277951% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|